Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126450271 | 12645027 | 1 | I | 2011 | 20160727 | 20160811 | 20160811 | EXP | E2B_00513163 | CA-HQ SPECIALTY-CA-2016INT000731 | INTERCHEM | 37.00 | YR | F | Y | 0.00000 | 20160811 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126450271 | 12645027 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 2.1429 MG (15 MG,1 IN 1 W) | 201749 | ||||||||||
| 126450271 | 12645027 | 2 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 2.8571 MG (20 MG,1 IN 1 W) | 201749 | ||||||||||
| 126450271 | 12645027 | 3 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | UNK | 201749 | |||||||||||
| 126450271 | 12645027 | 4 | SS | ENBREL | ETANERCEPT | 1 | Subcutaneous | UNK | Y | 0 | |||||||||
| 126450271 | 12645027 | 5 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | UNK | Y | 0 | ||||||||||
| 126450271 | 12645027 | 6 | SS | PLAQUENIL /00072602/ | HYDROXYCHLOROQUINE DIPHOSPHATE | 1 | UNK | Y | 0 | ||||||||||
| 126450271 | 12645027 | 7 | SS | GOLD | GOLD | 1 | UNK | Y | 0 | ||||||||||
| 126450271 | 12645027 | 8 | SS | RITUXAN | RITUXIMAB | 1 | Intravenous (not otherwise specified) | UNK | Y | 0 | |||||||||
| 126450271 | 12645027 | 9 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | UNK | Y | 0 | |||||||||
| 126450271 | 12645027 | 10 | SS | ORENCIA | ABATACEPT | 1 | UNK | Y | 0 | ||||||||||
| 126450271 | 12645027 | 11 | SS | ACTEMRA | TOCILIZUMAB | 1 | UNK | 0 | |||||||||||
| 126450271 | 12645027 | 12 | SS | ACTEMRA | TOCILIZUMAB | 1 | (8 MG/KG) | 0 | |||||||||||
| 126450271 | 12645027 | 13 | SS | PREDNISONE. | PREDNISONE | 1 | (50 MG,1 D) | 0 | |||||||||||
| 126450271 | 12645027 | 14 | SS | PREDNISONE. | PREDNISONE | 1 | Oral | 5 MG (5 MG,1 IN 1 D) | 0 | ||||||||||
| 126450271 | 12645027 | 15 | SS | PREDNISONE. | PREDNISONE | 1 | Oral | (3 MG,1 D) | 0 | ||||||||||
| 126450271 | 12645027 | 16 | SS | NAPROSYN | NAPROXEN | 1 | UNK | 0 | |||||||||||
| 126450271 | 12645027 | 17 | C | LOSEC | OMEPRAZOLE | 1 | UNK | U | 0 | ||||||||||
| 126450271 | 12645027 | 18 | C | CELEXA | CITALOPRAM HYDROBROMIDE | 1 | UNK | U | 0 | ||||||||||
| 126450271 | 12645027 | 19 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | UNK | U | 0 | ||||||||||
| 126450271 | 12645027 | 20 | C | CITALOPRAM HYDROBROMIDE. | CITALOPRAM HYDROBROMIDE | 1 | UNK | U | 0 | ||||||||||
| 126450271 | 12645027 | 21 | C | ROSUVASTATIN CALCIUM. | ROSUVASTATIN CALCIUM | 1 | UNK | U | 0 | ||||||||||
| 126450271 | 12645027 | 22 | C | XELJANZ | TOFACITINIB CITRATE | 1 | UNK | U | 0 | ||||||||||
| 126450271 | 12645027 | 23 | C | KETOPROFEN. | KETOPROFEN | 1 | 200 MG (100 MG,2 IN 1 D) | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126450271 | 12645027 | 1 | Rheumatoid arthritis |
| 126450271 | 12645027 | 4 | Rheumatoid arthritis |
| 126450271 | 12645027 | 5 | Rheumatoid arthritis |
| 126450271 | 12645027 | 6 | Rheumatoid arthritis |
| 126450271 | 12645027 | 7 | Rheumatoid arthritis |
| 126450271 | 12645027 | 8 | Rheumatoid arthritis |
| 126450271 | 12645027 | 9 | Rheumatoid arthritis |
| 126450271 | 12645027 | 10 | Rheumatoid arthritis |
| 126450271 | 12645027 | 11 | Rheumatoid arthritis |
| 126450271 | 12645027 | 13 | Rheumatoid arthritis |
| 126450271 | 12645027 | 16 | Product used for unknown indication |
| 126450271 | 12645027 | 17 | Product used for unknown indication |
| 126450271 | 12645027 | 18 | Product used for unknown indication |
| 126450271 | 12645027 | 19 | Product used for unknown indication |
| 126450271 | 12645027 | 20 | Product used for unknown indication |
| 126450271 | 12645027 | 21 | Product used for unknown indication |
| 126450271 | 12645027 | 22 | Product used for unknown indication |
| 126450271 | 12645027 | 23 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126450271 | 12645027 | HO |
| 126450271 | 12645027 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126450271 | 12645027 | Asthenia | |
| 126450271 | 12645027 | Cough | |
| 126450271 | 12645027 | Drug ineffective | |
| 126450271 | 12645027 | Fatigue | |
| 126450271 | 12645027 | Fine motor skill dysfunction | |
| 126450271 | 12645027 | Goitre | |
| 126450271 | 12645027 | Headache | |
| 126450271 | 12645027 | Knee arthroplasty | |
| 126450271 | 12645027 | Lower respiratory tract infection | |
| 126450271 | 12645027 | Nasopharyngitis | |
| 126450271 | 12645027 | Nephrolithiasis | |
| 126450271 | 12645027 | Rheumatoid arthritis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126450271 | 12645027 | 1 | 19960101 | 2015 | 0 | |
| 126450271 | 12645027 | 2 | 2015 | 20150910 | 0 | |
| 126450271 | 12645027 | 4 | 20150701 | 0 | ||
| 126450271 | 12645027 | 11 | 20150910 | 0 | ||
| 126450271 | 12645027 | 13 | 20070101 | 0 | ||
| 126450271 | 12645027 | 14 | 2015 | 0 | ||
| 126450271 | 12645027 | 15 | 2015 | 0 |